SavedAdd your journal

Journals / Medicine Science / 2022 / Cilt: 11 - Sayı: 1

Evaluation of the relationship between COVID-19 and hyperglycemia

Seval Müzeyyen ECİN
Deniz GEZER
Pages
85–89
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Advanced age (OR: 1.0, 95% CI: 1.0-1.1, p: 0.03) and mutant strain (OR:0.1, 95% CI: 0.1-0.3, p:

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enters cells via the angiotensin-converting enzyme.
📊
Key Findings & Data:Hyperglycemia is an independent risk factor that increases the mortality and morbidity of COVID-19.
💡
Conclusion & Impact:Advanced age (OR: 1.0, 95% CI: 1.0-1.1, p: 0.03) and mutant strain (OR:0.1, 95% CI: 0.1-0.3, p:
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enters cells via the angiotensin-converting enzyme. This enzyme is found in many organs, including the pancreas. Thus, the virus enters the pancreatic islets via this enzyme and causes acute hyperglycemia by triggering acute beta-cell dysfunction. Hyperglycemia is an independent risk factor that increases the mortality and morbidity of COVID-19. Therefore, we aimed to evaluate the presence of elevated glucose levels and/or DM in COVID-19 patients and their relationship with clinical findings, biochemical and inflammatory markers, and prognosis of COVID-19. The study included 300 patients. Advanced age (OR: 1.0, 95% CI: 1.0-1.1, p: 0.03) and mutant strain (OR:0.1, 95% CI: 0.1-0.3, p:

🔖

Cite This Article

ECİN, S. M., GEZER, D. (2022). Evaluation of the relationship between COVID-19 and hyperglycemia. Medicine Science, Cilt: 11 - Sayı: 1, 85–89. https://ajindex.com/articles/579511

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lui DTW, Lee CH, Chow WS, et al. A territory-wide study on the impact of COVID-19 on diabetes-related acute care. J Diabetes Investig. 2020;11:1303-6
  2. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843
  3. Zhu N, Zhang D, Wang W, et al. ChinaNovel Coronavirus Investigating and Research Team A novel coronavirus from patients withpneumonia in China, 2019. N Engl J Med. 2020;382:727–33
  4. Li H, Liu SM, Yu XH, et al. Coronavirus disease 2019 (CO VID-19): current statusand future perspectives. Int J Antimicrob Agents. 2020;55:105951
  5. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;e3319
  6. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of coronavirus disease 2019 in china. N Engl J Med. 2020;382:1708‐20
  7. Izumi Y, Hidaka Y, Tada H, et al. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves’ thyrotoxicosis. Clin Endocrinol (Oxf). 2002;57:51-8
  8. Umpierrez GE, Hellman R, Korytkowski MT, el al. Management of hyperglycemia in hospitalized patients in non-critical care setting: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol. 2012;97:16–38
  9. Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: outcomes in hypertensive cohort andcontroversies with renin angiotensin system blockers. Diabetes Metabol Syndrome Res Rev. 2020;14:283-7
  10. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and metaanalysis. Int J Infect Dis. 2020 Mar 12 doi: 10.1016/j.ijid.2020.03.017. pii: S1201-9712(20)30136-3
  11. Epidemiology Working Group for Ncip Epidemic Response The epidemiological characteristics ofan outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Chin J Epidemiol. 2020;41:145–51
  12. Preliminary estimates of the prevalence of selected underlying health conditions among patientswith coronavirus disease 2019 — United States, february 12–march 28, 2020.CDC COVID-19response team
  13. Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages isletsand causes acute diabetes. Acta Diabetol. 2010;47
  14. Cheng H, Wang Y, Wang G‐Q. Organ‐protective effect of angiotensinconverting